INHSU regularly supports the development and dissemination of clinical practice guidelines that impact the health of people who use drugs.
Examples of INHSU guidelines and recommendations include:
- 2015: INHSU contributed to a special edition of the International Journal of Drug Policy, compiling the 2nd revision of the “International recommendations for the management of HCV among people who use drugs”
- 2016: INHSU submitted an editorial to the Journal of Hepatology highlighting contradictory advice for people who inject drugs in the 2016 European Association for the Study of the Liver (EASL) Clinical Guidelines on recommendations for the treatment of hepatitis C. INHSU strongly recommended that all restrictions to access to HCV treatments based on drug or alcohol use or opioid substitution treatment be removed. Following this, EASL ensured the evidence supporting offering HCV treatment to all people who use drugs was included, and the wording in the 2016 Recommendations was revisited
- 2017: INHSU guest-edited a special issue in the International Journal of Drug Policy entitled “Elimination of hepatitis C virus infection among people who inject drugs: The beginning of a new era of interferon-free DAA therapy”
- 2017: In collaboration with colleagues from the International AIDS Society (IAS), INHSU wrote an editorial in the Journal of the International AIDS Society entitled “Elimination of HCV as a public health concern among people who inject drugs by 2030: What will it take to get there?”
- 2017: INHSU was involved in evaluating restrictions for reimbursement of DAA therapy for HCV infection in Europe, which was published by the Lancet Gastroenterology & Hepatology
- 2018: Following advocacy efforts regarding language in the 2016 Recommendations, INHSU collaborated with EASL to ensure that the EASL Recommendations on Treatment of Hepatitis C 2018 incorporated the most up to date data to guide the clinical HCV management of HCV infection among people who use drugs
- 2018: INHSU produced an article in Liver International discussing challenges and recommendations for HCV elimination in PWID within a health systems framework. The piece provides specific examples to enhance clinical practice across 7 health systems components